Recurrent XXXX in Central @entity2994 Treated with Intravitreal Ranibizumab using a Modified Treat and Extend Regimen.

@entity1 @entity2994 @entity21324 @entity1103
UNASSIGNED: Background: The aim of this study was to evaluate the stability over time of the individually defined interval of intravitreal ranibizumab injection (IVR) for the treatment of recurrent @entity1103 ( @entity1103 ) in central @entity2994 (CRVO). @entity1 and Methods: A case series of treatment na  ve @entity1 followed in the Jules Gonin Eye Hospital for @entity1103 due to central @entity2994 is presented. @entity1 were treated monthly with IVR until complete absence of fluid on qualitative SD-OCT with a minimum of 5 monthly IVR. Thereafter, they were followed according to a modified treat and extend regimen ( @entity21324 ). Results: Twelve eyes (12 @entity1 ) with @entity1103 due to CRVO were included. The mean follow-up period was 31.3 months. Analysis showed that best corrected visual acuity (BCVA), central macular thickness and qualitative spectral domain optical coherence tomography (SD-OCT) showed comparable results under monthly interval, after titration of an individualized interval and when performed in a series. 78% of treating intervals were within      2 weeks of the first individually adjusted interval. The mean first defined interval was 4.3 weeks and the mean interval over time was 5.5 weeks (p   =   0.003). There was a trend towards longer interval over time. Conclusion: The adjusted interval of retreatment of @entity1 with @entity1103 due to CRVO showed a high stability with a trend toward longer duration over time. An @entity21324 regimen seems to be valuable to follow @entity1 with @entity1103 with good stabilization of VA.
